14比1,信达PD-1究竟败在哪儿?( 二 )


参考资料:
1.SintilimabBLA761222,FDAAdvisoryCommiteeBriefingDocumnet.
2.YangY,WangZ,FangJ,etal.EfficacyandSafetyofSintilimabPlusPemetrexedandPlatinumasFirst-LineTreatmentforLocallyAdvancedorMetastaticNonsquamousNSCLC:aRandomized,Double-Blind,Phase3Study(OncologypRogrambyInnovENTanti-PD-1-11)[J].JThoracOncol,2020,15(10):1636-1646.
14比1,信达PD-1究竟败在哪儿?】3.YangY,SunJ,WangZ,etal.UpdatedOverallSurvivalDataandPredictiveBiomarkersofSintilimabPlusPemetrexedandPlatinumasFirst-LineTreatmentforLocallyAdvancedorMetastaticNon-squamousNSCLCinthePhaseⅢORIENT-11Study[J].JThoracOncol,2021,Aug3:S1556-0864(21)02330-3.